Saswati Hazra1, Steven M Dubinett. 1. Lung Cancer Research Program of the Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Shazra@mednet.ucla.edu
Abstract
BACKGROUND: Cyclooxygenase-2 (COX-2) over-expression and subsequent prostaglandin E2 (PGE2) production are frequently associated with human non-small-cell lung cancer (NSCLC) and are involved in tumor proliferation, invasion, angiogenesis, and resistance to apoptosis. Here, we report that ciglitazone downregulates PGE2 in NSCLC cells. METHODS: PGE2 ELISA assay and COX-2 ELISA assay were performed for measuring PGE2 and COX-2, respectively, in NSCLC. The mRNA level of COX-2 was measured by semi-quantitative RT-PCR. The transient transfection experiments were performed to measure COX-2 and peroxisome proliferator-response element (PPRE) promoter activity in NSCLC. Western blots were unitized to measure PGE synthase (PGES) and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) protein expression. RESULTS: COX-2 ELISA assays suggested that ciglitazone-dependent inhibition of PGE2 occurs through the suppression of COX-2. Ciglitazone treatment suppressed COX-2 mRNA expression and COX-2 promoter activity while upregulating PPRE promoter activity. Ciglitazone did not modify the expression of enzymes downstream of COX-2 including PGES and 15-PGDH. Utilization of a dominant-negative PPARgamma showed that the suppression of COX-2 and PGE2 by ciglitazone is mediated via non-PPAR pathways. CONCLUSION: Taken together, our findings suggest that ciglitazone is a negative modulator of COX-2/PGE2 in NSCLC.
BACKGROUND:Cyclooxygenase-2 (COX-2) over-expression and subsequent prostaglandin E2 (PGE2) production are frequently associated with human non-small-cell lung cancer (NSCLC) and are involved in tumor proliferation, invasion, angiogenesis, and resistance to apoptosis. Here, we report that ciglitazone downregulates PGE2 in NSCLC cells. METHODS:PGE2 ELISA assay and COX-2 ELISA assay were performed for measuring PGE2 and COX-2, respectively, in NSCLC. The mRNA level of COX-2 was measured by semi-quantitative RT-PCR. The transient transfection experiments were performed to measure COX-2 and peroxisome proliferator-response element (PPRE) promoter activity in NSCLC. Western blots were unitized to measure PGE synthase (PGES) and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) protein expression. RESULTS:COX-2 ELISA assays suggested that ciglitazone-dependent inhibition of PGE2 occurs through the suppression of COX-2. Ciglitazone treatment suppressed COX-2 mRNA expression and COX-2 promoter activity while upregulating PPRE promoter activity. Ciglitazone did not modify the expression of enzymes downstream of COX-2 including PGES and 15-PGDH. Utilization of a dominant-negative PPARgamma showed that the suppression of COX-2 and PGE2 by ciglitazone is mediated via non-PPAR pathways. CONCLUSION: Taken together, our findings suggest that ciglitazone is a negative modulator of COX-2/PGE2 in NSCLC.
Authors: M T Yip-Schneider; D S Barnard; S D Billings; L Cheng; D K Heilman; A Lin; S J Marshall; P L Crowell; M S Marshall; C J Sweeney Journal: Carcinogenesis Date: 2000-02 Impact factor: 4.944
Authors: M Gurnell; J M Wentworth; M Agostini; M Adams; T N Collingwood; C Provenzano; P O Browne; O Rajanayagam; T P Burris; J W Schwabe; M A Lazar; V K Chatterjee Journal: J Biol Chem Date: 2000-02-25 Impact factor: 5.157
Authors: M Stolina; S Sharma; Y Lin; M Dohadwala; B Gardner; J Luo; L Zhu; M Kronenberg; P W Miller; J Portanova; J C Lee; S M Dubinett Journal: J Immunol Date: 2000-01-01 Impact factor: 5.422
Authors: Jeanette L Grant; Michael C Fishbein; Long-Sheng Hong; Kostyantyn Krysan; John D Minna; Jerry W Shay; Tonya C Walser; Steven M Dubinett Journal: Cancer Prev Res (Phila) Date: 2013-11-19
Authors: Anthony J Apostoli; Jennifer M Roche; Mark M Schneider; Sandip K SenGupta; Michael A Di Lena; Rachel E Rubino; Nichole T Peterson; Christopher J B Nicol Journal: Mol Cancer Date: 2015-04-15 Impact factor: 27.401